Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies

Jia Yang, Junjie Shangguan, Aydin Eresen, Yu Li, Jian Wang, Zhuoli Zhang*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Despite significant advances over the past decades of research, pancreatic cancer (PC) continues to have the worst 5-year survival of any malignancy. Dendritic cells (DCs) are the most potent professional antigen-presenting cells and are involved in the induction and regulation of antitumor immune responses. DC-based immunotherapy has been used in clinical trials for PC. Although safety, efficacy, and immune activation were reported in patients with PC, DC vaccines have not yet fulfilled their promise. Additional strategies for combinatorial approaches aimed to augment and sustain the antitumor specific immune response elicited by DC vaccines are currently being investigated. Here, we will discuss DC vaccination immunotherapies that are currently under preclinical and clinical investigation and potential combination approaches for treating and improving the survival of PC patients.

Original languageEnglish (US)
Article number152691
JournalPathology Research and Practice
Issue number12
StatePublished - Dec 2019


  • Combination therapies
  • Dendritic cells
  • Pancreatic cancer
  • Vaccine

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology


Dive into the research topics of 'Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies'. Together they form a unique fingerprint.

Cite this